AzTrials
AzTrials

Meniscus TearFCARNCT06541756

Fibrine Clot-augmented Repair of Longitudinal Meniscus Tears

A study testing Fibrine Clot-augmented Meniscal Repair and Conventional Meniscal Repair in people with Meniscus Tear and Meniscus Lesion, run by Ankara City Hospital Bilkent at 2 sites in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Longitudinal meniscal tears are a type of meniscal injury characterized by a displaced fragment of the meniscus that flips over into the joint, often resembling a buckle or handle. These tears typically occur in the medial meniscus and are often associated with traumatic knee injuries, particularly in athletes. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Meniscus Tear, Meniscus Lesion, Fibrin Blood Clot
What is being tested?
Fibrine Clot-augmented Meniscal Repair and Conventional Meniscal Repair
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
2 sitesTurkey (Türkiye)
Study dates
25 Jul 2024to 31 Jul 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Presenting with a painful meniscus (lateral or medial) longitudinal tear
  • Being between the ages of 18 and 50
  • Not having undergone surgery on the same knee before
  • Having an MRI taken at the end of the 1st year post-surgery

Who cannot join

  • Having additional collateral ligamentous damage along with the meniscus tear (such as MCL or LCL)
  • Incomplete clinical scores at the end of the study
  • A history of previous surgery on the same knee
  • Having an active infection
  • Not having a control MRI at the end of the 1st year

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Enejd Veizi, MD contact

+905439799959

dr.nad89@hotmail.com

Yasin Erdoğan, MD contact

+905056056097

yasin-erdgn@hotmail.com

Turkey (Türkiye)2 sites, 2 recruiting
  • Ankara Bilkent City Hospital

    Ankara, 06000

    Enejd Veizi, MD, +905439799959, dr.nad89@hotmail.com

    Recruiting
  • Ankara Etlik City Hospital

    Ankara, 06000

    Yasin Erdoğan, MD, +905056056097, yasin-erdgn@hotmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Fibrine Clot-augmented Repair of Longitudinal Meniscus Tears - A Prospectively Randomized Controlled Trial

Longitudinal meniscal tears are a type of meniscal injury characterized by a displaced fragment of the meniscus that flips over into the joint, often resembling a buckle or handle. These tears typically occur in the medial meniscus and are often associated with traumatic knee injuries, particularly in athletes.

The displaced meniscal fragment can cause mechanical symptoms such as locking, clicking, or catching of the knee, as well as pain and swelling. If not properly treated, buckle-handle meniscal tears can lead to further complications, including chronic knee instability, increased risk of osteoarthritis, and persistent joint pain.Repairing a longitudinal meniscal tear offers several advantages over partial meniscectomy, particularly in preserving knee function and preventing long-term complications.

Read more

Meniscal repair aims to restore the integrity of the meniscus, which plays a crucial role in load distribution, shock absorption, and joint stability.

Utilizing a fibrin clot during the repair of a buckle-handle meniscal tear can enhance the healing process and improve surgical outcomes. Fibrin clots act as a biological scaffold, promoting tissue regeneration by providing a matrix that facilitates cellular migration and proliferation.

The purpose of this study was to compare longitudinal meniscal tear repair reinforced with fibrin clot with routine end-to-end repair in a prospective randomized controlled trial.

Read the detailed description

This study is designed as a prospective randomized controlled clinical trial. It aims to include patients presenting to the Orthopedics and Traumatology clinics at Ankara Bilkent and Etlik City Hospitals with longitudinal meniscus tears between August 2024 and December 2028. Participants will be randomly assigned to one of two groups: one receiving meniscus repair with fibrin clot reinforcement and the other receiving standard repair.

Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures, with spinal anesthesia. For the fibrin clot group, a fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures. After completing the repairs, the surgical wounds and portals will be closed, and an elastic bandage will be applied. The post-operative rehabilitation protocols will be the same for all patients.

Patients will be clinically followed for at least one year, with healing rates compared using control magnetic resonance imaging at the end of the first year.

Being tested
Fibrine Clot-augmented Meniscal Repair, Conventional Meniscal Repair
Medical subject headings
Knee Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fibrine Clot-augmented Meniscal RepairProcedure or surgery

    The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.

  • Conventional Meniscal RepairProcedure or surgery

    Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.

Study groups in NCT06541756
Study groupRoleWhat they receive
Fibrin Clot-augmented groupExperimentalPatients in the experimental repair group will undergo routine meniscus repair surgery in addition to a fibrin clot placed within the ruptured sides using arthroscopic all-inside or inside-out sutures. The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
Receives: Procedure: Fibrine Clot-augmented Meniscal Repair
Conventionally repaired groupActive comparatorPatients in the control repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures. The ruptured sides will be approximated as usual and the procedure will be considered completed.
Receives: Procedure: Conventional Meniscal Repair

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients with a healed meniscus on MRI

    Meniscal healing at 1 year follow up as detected on the control MRI (yes / no / partial)

    Measured: Postoperative 1st year

Secondary outcomes (3)
  1. Tegner Activity Scale

    minimum value:0, maximum value 10, higher values mean better outcome

    Measured: Postoperative 1.st year

  2. The Knee injury and Osteoarthritis Outcome Score (KOOS)

    minimum value:0, maximum value 100, higher values mean better outcome

    Measured: Postoperative 1.st year

  3. Tegner-Lysholm Score

    minimum value:0, maximum value 100, higher values mean better outcome

    Measured: Postoperative 1.st year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2024
  2. Study start25 Jul 2024
  3. Primary completion31 Jul 2028 (estimated)
  4. Study completion31 Jul 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective Randomized Controlled Study
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06541756
Sponsor's protocol ID
E2-24-7900
Acronym
FCAR
Status last verified
Sep 2025
First submitted
1 Aug 2024
Last updated
2 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Keller RE, O'Donnell EA, Medina GIS, Linderman SE, Cheng TTW, Sabbag OD, Oh LS. Biological augmentation of meniscal repair: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2022 Jun;30(6):1915-1926. doi: 10.1007/s00167-021-06849-5. Epub 2022 Mar 8.

    PubMed 35258647
  • Chrysanthou C, Laliotis N, Paraskevas GK, Anastasopoulos N, Packer G. Enhancing Meniscal Repair: Investigating the Impact of an Exogenous Fibrin Clot. Cureus. 2024 Jan 27;16(1):e53083. doi: 10.7759/cureus.53083. eCollection 2024 Jan.

    PubMed 38288322
  • Rodriguez AN, Reist H, Liechti DJ, Geeslin AG, LaPrade RF. Shuttling Technique for Directed Fibrin Clot Placement During Augmented Inside-Out Repair of Horizontal Meniscus Tears. Arthrosc Tech. 2022 Nov 17;11(12):e2205-e2211. doi: 10.1016/j.eats.2022.08.027. eCollection 2022 Dec.

    PubMed 36632380
  • Kinoshita T, Hashimoto Y, Orita K, Iida K, Takahashi S, Nakamura H. Bone Marrow-Derived Fibrin Clots Stimulate Healing of a Knee Meniscal Defect in a Rabbit Model. Arthroscopy. 2023 Jul;39(7):1662-1670. doi: 10.1016/j.arthro.2022.12.013. Epub 2022 Dec 24.

    PubMed 36574822
  • Kale S, Deore S, Gunjotikar A, Singh S, Ghodke R, Agrawal P. Arthroscopic meniscus repair and augmentation with autologous fibrin clot in Indian population: A 2-year prospective study. J Clin Orthop Trauma. 2022 Aug 6;32:101969. doi: 10.1016/j.jcot.2022.101969. eCollection 2022 Sep.

    PubMed 36035781

Questions about this trial

What is this clinical trial studying?

A study testing Fibrine Clot-augmented Meniscal Repair and Conventional Meniscal Repair in people with Meniscus Tear and Meniscus Lesion, run by Ankara City Hospital Bilkent at 2 sites in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Enejd Veizi, MD (+905439799959, dr.nad89@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients with a healed meniscus on MRI (time frame: Postoperative 1st year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06541756, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in